"Neutralizing monoclonal antibodies (mAbs) can stimulate

protective immunity. Hence their rapid identification and

characterization are incorporated into clinical practice to

provide effective treatment and prophylaxis during the

COVID-19 pandemic. Previously, mAbs have been

effectively used in several other viral infections, including

Ebola, influenza, HIV, RSV, Zika virus, and MERS-CoV.

Currently, the utilization of mAbs appears to have

favorable clinical outcomes in patients with mildmoderate SARS-CoV-2 infection, particularly individuals

at high risk of hospitalization and progression to severe

COVID-19. However, most of the interim results on antiSARS-CoV-2 mAbs are based on ongoing clinical trial

data; thereby, several questions revolve around this novel

therapy, including its long-term implication, application,

and feasibility. Although, the use of neutralizing mAbs

may assist in alleviating the critical burden on healthcare

settings and minimizing hospital stay due to severe

progression of the COVID-19 symptoms especially

among those with poor immune responses to vaccination,

elderly, and/or vaccine-refractory individuals.

Nonetheless, there is a broader need to explore these - novel therapies for their effective use in clinical practice

and to improve patient-related outcomes. "